NCT06347861View on ClinicalTrials.gov

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

July 22, 2024

Study Completion Date

August 8, 2024

Conditions
Healthy
Interventions
DRUG

single dose of vepdegestrant as tablet formulation (Treatment A)

phase 3 tablets

DRUG

single dose of vepdegestrant as tablet formulation (Treatment B)

registration tablets

DRUG

single dose of vepdegestrant as tablet formulation (Treatment C)

registration tablets

Trial Locations (1)

55114

Prism Research LLC dba Nucleus Network, Saint Paul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT06347861 - A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults | Biotech Hunter | Biotech Hunter